CUMBERLAND, R.I.–(BUSINESS WIRE)–Neurotech Pharmaceuticals, Inc. (the “Company”) today provided an update on its ongoing transition to a commercial‑stage company following the first anniversary of the FDA’s approval of ENCELTO™ (taroretcel-lwey), the…
Author: Business Wire
Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients
JACKSONVILLE, Fla.–(BUSINESS WIRE)–Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients
Heru Showcases PretestPro™ for the Heru VR-Powered Diagnostic Headset at Vision Expo
MIAMI–(BUSINESS WIRE)– #AIPoweredVisionDiagnostics–Heru, the leader in AI-powered vision diagnostics, announced it is showcasing the new PretestPro on its Heru wearable platform at Vision Expo 2026.
Aurion Biotech Appoints World Renowned Cornea Surgeon Marjan Farid, M.D., to Chair Medical Advisory Board
SEATTLE & CAMBRIDGE, Mass. & TOKYO–(BUSINESS WIRE)– #AurionBiotech–Aurion Biotech, Inc. (“Aurion”), a commercial-stage regenerative cell therapy company dedicated to restoring vision and working toward a future where blindness is eliminated, today a…
Sightview Unveils Fresh Patient Engagement Tools at Vision Expo 2026
DURHAM, N,C.–(BUSINESS WIRE)– #Automation–Sightview will showcase two recently updated tools for its eyecare-specific EHR/PM offering at Vision Expo 2026. See demos in booth #4021.
National Vision Announces Winners of 11th Annual Scholarship Program
DULUTH, Ga.–(BUSINESS WIRE)–National Vision Announces Winners of 11th Annual Scholarship Program
Qlaris Bio Appoints Fred Guerard, Pharm.D., as President and Chief Executive Officer
DEDHAM, Mass.–(BUSINESS WIRE)–Qlaris Bio, Inc. (“Qlaris”), a clinical-stage biotechnology company developing first-in-class therapies for glaucoma, today announced the appointment of Fred Guerard, Pharm.D., as president and chief executive officer (C…
Bausch + Lomb Launches R&D “Teach-in” Webinar Series
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the first event in an R&D “Teach-in” webinar series that will …
GenSight Biologics fait le point sur les programmes d’accès précoce de GS010/LUMEVOQ® et sur l’étude REVISE en cours
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (« GenSight Biologics » ou la « Société ») (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), société biopharmaceutique en phase clinique, spécialisée dans le développement et la comme…
GenSight Biologics Provides Updates about GS010/LUMEVOQ® Early Access Programs and the Ongoing REVISE Study
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and cent…
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #LineageCellTherapeutics–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious med…
Lucidis® établit des normes élevées en matière de chirurgie de la cataracte haut de gamme grâce à des performances visuelles complètes
NEUCHÂTEL, Suisse–(BUSINESS WIRE)–Swiss Advanced Vision annonce de nouvelles preuves cliniques confirmant les performances exceptionnelles de sa lentille intraoculaire Lucidis®, renforçant ainsi sa position de solution novatrice en chirurgie de la ca…
National Vision Holdings, Inc. Reports Fourth Quarter and Fiscal 2025 Financial Results
DULUTH, Ga.–(BUSINESS WIRE)–National Vision Holdings, Inc. (NASDAQ: EYE) (“National Vision” or the “Company”) today reported its financial results for the fourth quarter and fiscal year ended January 3, 2026, and is providing its outlook for fiscal 2…
STAAR Surgical Issues Shareholder Letter
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today issued a Shareholder Letter on Tuesday, March 3 af…
STAAR Surgical Reports Fourth Quarter and Fiscal Year 2025 Results
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the fourth quarter and fiscal…
ZEISS Vision Care and Medical Eyeglass Center Form Strategic Partnership, Combining Optical Excellence with Patient-Centric Operational Systems
HEBRON, Ky.–(BUSINESS WIRE)–ZEISS Vision Care, one of the world’s leading manufacturers of eyeglass lenses and ophthalmic instruments, today announced a strategic partnership with Medical Eyeglass Center (MEC), a nationally recognized, full-service o…
Samenvatting: Lucidis® stelt hoge normen voor hoogwaardige cataractchirurgie met volledig gezichtsvermogen
NEUCHÂTEL, Zwitserland–(BUSINESS WIRE)–Swiss Advanced Vision maakt nieuwe klinische resultaten bekend die de uitzonderlijke prestaties van zijn Lucidis® intraoculaire lens (IOL) bevestigen, waardoor zijn positie als baanbrekende oplossing in hoogwaar…
Riassunto: Lucidis® fissa standard elevati negli interventi di cataratta di alta qualità con prestazioni visive complete
NEUCHÂTEL, Svizzera–(BUSINESS WIRE)–Swiss Advanced Vision annuncia nuova evidenza clinica che conferma le eccezionali prestazioni della sua lente intraoculare (IOL) Lucidis®, rafforzando la sua posizione come soluzione innovativa nella chirurgia dell…
Lucidis® estabelece padrões elevados na cirurgia de catarata premium com desempenho visual completo
NEUCHÂTEL, Suíça–(BUSINESS WIRE)–A Swiss Advanced Vision anuncia novas evidências clínicas que confirmam o desempenho excepcional de sua lente intraocular (LIO) Lucidis®, fortalecendo sua posição como uma solução inovadora na cirurgia de catarata pre…
Lucidis®凭借全视程视觉表现，为高端白内障手术树立高标准
瑞士纳沙泰尔–(BUSINESS WIRE)–(美国商业资讯)– Swiss Advanced Vision公布最新临床证据，证实其Lucidis®人工晶体(IOL)表现卓越，进一步巩固其作为高端白内障手术颠覆性解决方案的地位。与传统的景深扩展型(EDOF)人工晶体不同，Lucidis®可提供媲美高端三焦点IOL的全视程视觉表现，同时保留对比敏感度、视觉质量，并将光晕和眩光等副作用降至最低，这也是其专利全折射式设计的标志性特征。 近期一项经同行评审的研究——由H. Naftali、W. Nas…